PMID- 32172363
OWN - NLM
STAT- MEDLINE
DCOM- 20210212
LR  - 20210602
IS  - 1432-1041 (Electronic)
IS  - 0031-6970 (Print)
IS  - 0031-6970 (Linking)
VI  - 76
IP  - 6
DP  - 2020 Jun
TI  - Proton pump inhibitors and risk of liver cancer and mortality in patients with 
      chronic liver disease: a systematic review and meta-analysis.
PG  - 851-866
LID - 10.1007/s00228-020-02854-8 [doi]
AB  - BACKGROUND: Epidemiological studies investigating the use of proton pump 
      inhibitors (PPI) on the risk of liver cancer and/or mortality among persons with 
      chronic liver disease (CLD) have reported conflicting results. We conducted a 
      systematic review and meta-analysis to determine the impact of PPI use on liver 
      cancer and/or death among patients with CLD. METHODS: The core databases 
      including MEDLINE, EMBASE, and Cochrane library were searched through January 
      2020. We included studies, evaluating the association between PPIs and liver 
      cancer or mortality among patients with CLD including randomized controlled, 
      nonrandomized controlled, and observational studies. We used inverse-variance 
      random-effects models to estimate the pooled relative risk (RR) and 95% 
      confidence interval (CI) for liver cancer or mortality. RESULTS: Eleven studies 
      including 173,894 patients were selected. In three studies, individuals with CLD 
      who used PPIs had a 67% greater risk of developing hepatocellular carcinoma (HCC) 
      compared to nonusers (RR, 1.67; 95% CI, 1.12-2.50; I(2) = 92%). Combining data 
      from the eight studies relating PPI to overall mortality, we observed a 57% 
      increased risk of mortality in PPI users with CLD compared to CLD nonusers (RR: 
      1.57; 95% CI, 1.24-1.99; I(2) = 69%). CONCLUSION: PPI use was associated with an 
      increased risk of HCC and mortality in patients with CLD suggesting that PPI 
      prescriptions in patients with CLD should be considered carefully.
FAU - Song, Hyun Jin
AU  - Song HJ
AUID- ORCID: 0000-0003-4779-6555
AD  - Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University 
      of Florida, 1225 Center Drive, Gainesville, 32610, FL, USA.
AD  - Department of Pharmaceutical Policy and Outcomes Research, School of Pharmacy, 
      Sungkyunkwan University, Suwon, South Korea.
FAU - Jiang, Xinyi
AU  - Jiang X
AD  - Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University 
      of Florida, 1225 Center Drive, Gainesville, 32610, FL, USA.
FAU - Henry, Linda
AU  - Henry L
AD  - Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University 
      of Florida, 1225 Center Drive, Gainesville, 32610, FL, USA.
FAU - Nguyen, Mindie H
AU  - Nguyen MH
AD  - Division of Gastroenterology and Hepatology, Stanford University Medical Center, 
      Palo Alto, CA, USA.
FAU - Park, Haesuk
AU  - Park H
AUID- ORCID: 0000-0003-3299-8111
AD  - Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University 
      of Florida, 1225 Center Drive, Gainesville, 32610, FL, USA. hpark@cop.ufl.edu.
LA  - eng
GR  - K01 DA045618/DA/NIDA NIH HHS/United States
GR  - K01DA045618/National Institute on Drug Abuse of the National Institutes of 
      Health/
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20200314
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - Carcinoma, Hepatocellular/*chemically induced/*mortality
MH  - Humans
MH  - Liver Neoplasms/*chemically induced/*mortality
MH  - Proton Pump Inhibitors/*adverse effects
PMC - PMC7244371
MID - NIHMS1576666
OTO - NOTNLM
OT  - Chronic liver disease
OT  - Hepatocellular carcinoma
OT  - Liver cancer
OT  - Meta-analysis
OT  - Mortality
OT  - Proton pump inhibitor
OT  - Systematic review
COIS- Conflicts of Interest The authors declare that they have no competing interests.
EDAT- 2020/03/17 06:00
MHDA- 2021/02/13 06:00
PMCR- 2021/06/01
CRDT- 2020/03/16 06:00
PHST- 2019/12/02 00:00 [received]
PHST- 2020/03/05 00:00 [accepted]
PHST- 2020/03/17 06:00 [pubmed]
PHST- 2021/02/13 06:00 [medline]
PHST- 2020/03/16 06:00 [entrez]
PHST- 2021/06/01 00:00 [pmc-release]
AID - 10.1007/s00228-020-02854-8 [pii]
AID - 10.1007/s00228-020-02854-8 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 2020 Jun;76(6):851-866. doi: 10.1007/s00228-020-02854-8. 
      Epub 2020 Mar 14.